The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.
Year: 2001
Type: article
Source: PubMed
Authors: M M Moasser, A Basso, S D Averbuch, N Rosen
Institution: Memorial Sloan Kettering Cancer Center
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: National Cancer Institute
Award: SPORE IN BREAST CANCER
OpenAlex ID: W1590794385